1260090-48-9

Upstream product

• 874291-00-6 1-ethyl-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]urea 
• 1260090-51-4 2-chloro-7-(2-methoxyethyl)-7-methyl-4-((S)-3-methylmorpholino)-5,7-dihydrofuro[3,4-d]pyrimidine 
• 1260090-18-3 ethyl 5-allyl-5-methyl-4-oxotetrahydrofuran-3-carboxylate 
• 1260090-21-8 (+/-)-ethyl 5-allyl-4-amino-5-methyl-2,5-dihydrofuran-3-carboxylate 
• 1260090-23-0 (+/-)-7-allyl-7-methyl-5,7-dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione 
• 1260089-81-3 (+/-)-7-allyl-2,4-dichloro-7-methyl-5,7-dihydrofuro[3,4-d]pyrimidine 
• 1293387-83-3 7-allyl-2-chloro-7-methyl-4-((S)-3-methylmorpholino)-5,7-dihydrofuro[3,4-d]pyrimidine 
• 1260090-50-3 2-(2-chloro-7-methyl-4-((S)-3-methylmorpholino)-5,7-dihydrofuro[3,4-d]pyrimidin-7-yl)ethanol 

Relevant academic research and scientific papers

Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine

Figure Presented. A series of inhibitors of mTOR kinase based on a quaternary-substituted dihydrofuropyrimidine was designed and synthesized. The most potent compounds in this series inhibited mTOR kinase with Ki 100 - ) selective for mTOR over the closely related PI3 kinases. Compounds in this series showed inhibition of the pathway and antiproliferative activity in cell-based assays. Furthermore, these compounds had excellent mouse PK, and showed a robust PK-PD relationship in a mouse model of cancer.

OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).